Navigation Links
Cephalon Submits Supplemental New Drug Application for FENTORA
Date:11/12/2007

e fatal to a child. Patients and their caregivers must be instructed to keep all tablets out of the reach of children. (See Information for Patients and Caregivers for disposal instructions.)

Due to the higher bioavailability of fentanyl in FENTORA, when converting patients from other oral fentanyl products, including oral transmucosal fentanyl citrate (OTFC and Actiq(R)), to FENTORA, do not substitute FENTORA on a mcg per mcg basis. Adjust doses as appropriate. (See DOSAGE AND ADMINISTRATION.)

FENTORA is intended to be used only in the care of opioid tolerant cancer patients and only by healthcare professionals who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.

The concomitant use of FENTORA with strong and moderate cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression.

Full prescribing information about FENTORA, including boxed warning, is available from http://www.FENTORA.com.

About Cephalon, Inc.

Cephalon, Inc. is an international biopharmaceutical company, recently inducted into the World Economic Forum Community of Global Growth Companies. For 20 years, the company has been dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. Cephalon has delivered a seven-year compound annual growth rate (CAGR) through 2006 greater than 75% and 2006 revenue of $1.760 billion. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters are loca
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
9. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
10. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
11. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... to release financial results for the first quarter of ... market close in the US.  The ... ET on Friday, August 29, 2014 to discuss its ... Company,s recent developments, followed by a question and answer ...
(Date:8/21/2014)... 2014 Pursuit Solutions ( http://www.pursuit-solutions.com ... and services for Life Sciences sales and marketing ... of New Commercial Sales Models” by Peter Robinson, ... The article examines some innovative models used to ... tested in the pharmaceutical market. Robinson grades the ...
(Date:8/21/2014)... August 21, 2014 Gallus ... contract development and manufacturing organization (CMO) announced today ... Inc., an oncology company focused on the development ... to manufacture the anti-prostate specific membrane antigen (PSMA) ... candidate. Under the agreement the antibody will ...
(Date:8/21/2014)... August 21, 2014 On Wednesday of last ... to use Redox Signaling molecules, became available for purchase in ... , "The way that RENU 28 works is, if you ... down of the rate of cellular renewal within your body. ... increasing of that rate of cellular renewal. What RENU 28 ...
Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2
... China , May 18 /PRNewswire-Asia/ -- Ningbo ... was officially put into operation, successfully being used in ... steel slag as an absorbent,instead of lime or other ... of lime agents, the replacement reduces SO2 emissions by,more ...
... CLEVELAND, Ohio , May 18, 2010 Simbionix USA Corporation,the ... and the healthcare industry, is proud to,report that their ANGIO Mentor virtual ... Societies in April 2010 for,the training and certification of vascular ... , , ...
... ... with ultra-fine finishing capabilities , ... (PRWEB) -- The increased miniaturization of medical devices such as surgical instruments ... the integral items that have helped to facilitate the use of miniaturized medical devices ...
Cached Biology Technology:TAIJI Announces Official Operation of Its Sintering FGD Project for Tangshan 2Simbionix ANGIO Mentor Plays Important Role in Physician Training and Certification 2Ultra-Fine Metal Tubing Smoothes the Way for Miniaturized Medical Devices 2Ultra-Fine Metal Tubing Smoothes the Way for Miniaturized Medical Devices 3
(Date:8/20/2014)... in in this image of the Para and Mato ... most likely intentionally set in order to deforest the ... stand of trees where the land is thereafter converted ... of forestland to farms, ranches, or urban use. The ... the Amazon Rainforest in the middle of the image ...
(Date:8/20/2014)... the Oklahoma Medical Research Foundation a five-year, $14.5 million ... bacteria,s effects on humans. , For 10 years, ... studied the human immune response to anthrax bacteria as ... original funding came soon after anthrax-laced letters killed five ... attacks of Sept. 11, 2001. , The long-term ...
(Date:8/20/2014)... seawater signals a relaxing trip to the shore. But ... comes with an environmental hitch. When certain sunblock ingredients ... become toxic to some of the ocean,s tiniest inhabitants, ... animals. Their study appears in the ACS journal ... David Snchez-Quiles point out that other than staying indoors, ...
Breaking Biology News(10 mins):$14.5 million grant awarded to continue anthrax studies 2
... shows that prenatal health care professionals are concerned about ... providing effective counseling. Rates of excessive weight gain ... adverse health outcomes for mothers and children, have increased ... care providers agree that weight gain is an important ...
... Palo Alto, CATo engineer better, more productive crops ... look at how the sensor-laden membranes surrounding cells ... interact with the environment and neighboring cells to ... about how proteins interact with these protective structures. ...
... to three-dimensional puzzles, Rubik,s Cube pales in comparison with ... Gordon and collaborators Chuck DeMets of the University of ... in Pasadena, Calif., have just put the finishing touches ... of the relative movements of the interlocking tectonic plates ...
Cached Biology News:Prenatal health-care providers inconsistent in weight-gain counseling 2Cracking the plant-cell membrane code 2Tectonics: Precision is hallmark of 20-year study 2Tectonics: Precision is hallmark of 20-year study 3
... tube luminometer provides the sensitivity and versatility ... Advanced digital photon counting with selected photomultipliers ... spectral demands. Equipped with up to 2 ... for reporter gene assays as well as ...
... convenient, and efficient native protein concentration following ... spin column to make handling easy. The ... which were electro-eluted in their native condition. ... high binding capacity fo all pH values. ...
MAb to HLA, Class II-DR+DP Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Cell Culture Flask, nontreated polystyrene...
Biology Products: